Trending Topic

Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience
15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

Search Results

Showing Results for clinical trial

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Prof. Joaquim Ferreira shares insights from EAN 2025 on the future of Parkinson’s disease care. He discusses realistic timelines for DMTs, the evolving role of gene therapy for genetic subgroups, and the potential of adaptive deep brain stimulation. Prof. Ferreira also highlights the growing importance of optimizing current treatments, interdisciplinary care, and addressing persistent challenges such as gait disturbance, dyskinesia, and cognitive decline.

Mark CompleteCompleted
BookmarkBookmarked

"Continued support for research, and for the patients themselves, is absolutely critical. I’m grateful for the opportunity to help bring some of this work to light." Dr Anissa Abi-Dargham is Chair of Psychiatry and Behavioral Health at the Renaissance ...

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.

Mark CompleteCompleted
BookmarkBookmarked

"it is great to find out that some reasoning and a prescription has helped someone turn their life around"   Dr Alexander Lisinski, resident psychiatrist at Sahlgrenska University Hospital and researcher at the Department of Pharmacology, Sahlgrenska Academy, Gothenburg, Sweden, ...

Mark CompleteCompleted
BookmarkBookmarked

Broadest approval to date in generalized myasthenia gravis The FDA approval of nipocalimab for generalized myasthenia gravis (gMG) introduces a targeted therapy within a validated class, offering the potential for durable disease control across the broadest patient population to date. ...

Mark CompleteCompleted
BookmarkBookmarked

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...

Coverage from: Key congresses 2025

n this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.

Mark CompleteCompleted
BookmarkBookmarked

 "this is a field where rigorous science can rapidly change lives"   Dr Bardia Nourbakhsh, Associate Professor of Neurology, Johns Hopkins University, Baltimore, MD, USA, is a rising star whose work bridges rigorous clinical neurological research with compassionate, patient-centred care. ...

Mark CompleteCompleted
BookmarkBookmarked

In this Q&A, Dr Andy Liu, Associate Professor of Neurology at Duke University School of Medicine, discusses his presentation on the clinical use of lecanemab in Alzheimer’s disease. Drawing on real-world experience and findings from the 2022 CLARITY AD study, Dr Liu explores the treatment’s benefits, challenges in daily practice and the importance of patient-centred care in this evolving therapeutic landscape.

Mark CompleteCompleted
BookmarkBookmarked
Pavel Burko, Ilias Miltiadis, Mahsa Alavi

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...

Mark CompleteCompleted
BookmarkBookmarked

touchNEUROLOGY is delighted to congratulate Dr Amit Bar-Or of Penn Medicine on receiving the 2025 John Dystel Prize for Multiple Sclerosis Research, jointly awarded by the National Multiple Sclerosis Society (NMMS) and the American Academy of Neurology (AAN). This honour recognizes his groundbreaking work in neuroimmunology, precision medicine, and biomarker research in multiple sclerosis (MS).

Mark CompleteCompleted
BookmarkBookmarked

The 2025 Annual Meeting of the American Academy of Neurology in San Diego brought together over 14,500 neurology professionals from 110 countries and all 50 US states, alongside more than 300 exhibiting companies. It was a week filled with inspiring science, learning, and global collaboration—all in support of advancing brain health for all. Among the many highlights were the late-breaking abstracts, showcasing some of the most exciting developments in neurology. From this impressive selection, we’ve chosen five standout presentations that reflect the innovation and momentum seen throughout the meeting.

Mark CompleteCompleted
BookmarkBookmarked

In this Q&A, Herbert Temmes shares why prevention is such a crucial and timely topic, how the MS community can be more involved in shaping decisions, and what outcomes he hopes the conference will deliver for years to come.

Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% ...

Mark CompleteCompleted
BookmarkBookmarked

Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...

50 mins
Sponsored Content

Sanofi at ECTRIMS 2024. Join MS experts as they examine disability accumulation through the lens of personalised care, biomarkers, and clinical trial design. Hear their perspectives on the complexities of balancing improved relapse management with the ongoing challenge of disability accumulation.

Mark CompleteCompleted
BookmarkBookmarked

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ...

Load More...
Close Popup